The role of mTOR inhibitors in kidney diseases;El papel de los inhibidores de mTOR en las enfermedades renales

Nefrologia

Volumn 31, Issue 3, 2011, Pages 251-255

  Pérez, J C Rodríguez ^a  

^a HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ARTICLE; DRUG ANTAGONISM; HUMAN; KIDNEY DISEASE; PHYSIOLOGY;

HUMANS; KIDNEY DISEASES; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 79959333784     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2011.Apr.10947     Document Type: Article

References (26)

1. Pérez Machín R, Rodríguez Díaz Y, Vega Hernández MC. La ruta mTOR como diana terapéutica. BioCancer 2006;3.
2. Masoumi A, Reed Gitomer B, Kelleher C, Schrier RW. Potential pharmacological interventions in polycystic kidney disease. Drugs 2007;67:2495-510.
3. Lieberthal W, Levine JS. The role of the mammalian target of rapamycin (mTOR) in renal disease. J Am Soc Nephrol 2009;20:2493-502.
4. Bonventre JV. Dedifferentiation and proliferation of surviving epithelial cells in acute renal failure. J Am Soc Nephrol 2003;14(Suppl 1):S55-S61.
5. Lieberthal W, Fuhro R, Andry CC, Rennke H, Abernathy VE, Koh JS, et al. Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 2001;281:F693-F706.
6. Lee CH, Inoki K, Guan KL. mTOR pathway as a target in tissue hypertrophy. Annu Rev Pharmacol Toxicol 2007;47:443-67.
7. Hostetter TH. Hyperfiltration and glomerulosclerosis. Semin Nephrol 2003;23:194-9.
8. Kasinath BS, Mariappan MM, Sataranatarajan K, Lee MJ, Feliers D. mRNA translation: Unexplored territory in renal science. J Am Soc Nephrol 2006;17:3281-92.
9. Lloberas N, Cruzado JM, Franquesa M, Herrero-Fresneda I, Torras J, Alperovich G, et al. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol 2006;17:1395-404.
10. Eddy AA, Neilson EG. Chronic kidney disease progression. J Am Soc Nephrol 2006;17:2964-6.
11. Bonegio RG, Fuhro R, Wang Z, Valeri CR, Andry C, Salant DJ, et al. Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol 2005;16:2063-72.
12. Aguiari G, Trimi V, Bogo M, Mangolini A, Szabadkai G, Pinton P, et al. Novel role for polycystin-1 in modulating cell proliferation through calcium oscillations in kidney cells. Cell Prolif 2008; 41:554-73.
13. Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N, et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA 2006;103:5466-71.
14. Baker H, Sidorowicz A, Sehgal SN, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic. III. In vitro and in vivo evaluation. J Antibiot (Tokyo) 1978;31:539-45.
15. Davies CB, Madden RL, Alexander JW. Effect of a short course of rapamycin, cyclosporin A, and donor-specific transfusion on rat cardiac allograft survival. Transplantation 1993;55:1107-12.
16. Trepanier DJ, Gallant H, Legatt DF, Yatscoff RW. Rapamycin: distribution, pharmacokinetics and therapeutic range investigations: an update. Clin Biochem 1998;31:345-51.
17. DiJoseph JF, Mihatsch MJ, Sehgal SN. Renal effects of rapamycin in the spontaneously hypertensive rat. Transpl Int 1994;7:83-8.
18. Andoh TF, Burdmann EA, Fransechini N, Houghton DC, Bennett WM. Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506. Kidney Int 1996;50:1110-7.
19. Sousa JE, Sousa AG, Costa MA, Abizaid AC, Feres F. Use of rapamycin-impregnated stents in coronary arteries. Transplant Proc 2003;35:165S-170S.
20. Cabrera López C, Martí T, Catalá V, Torres F, Mateu S, Ballarín Castán J, et al. Efectos de la rapamicina en los angiomiolipomas de pacientes con esclerosis tuberosa. Nefrologia 2011;31(3):292-8.
21. Krueger DA, Franz DN. Current Management of tuberous sclerosis complex. Paediatr Drugs 2008;10:299-313.
22. Bissler JJ, Kingswood JC. Renal angiomyolipomata. Kidney Int 2004;66:924-34.
23. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med 2006;355:1345-56.
24. Huang J, Manning BD. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J 2008;412:179-90.
25. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008; 358:140-51.
26. Wienecke R, Facler I, Linsenmaier U, Mayer K, Licht T, Kretzler M. Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex. Am J Kidney Dis 2006;48:E27-E29.